NewsSai Parenterals Limited Reports Nil Utilization of IPO Proceeds for Quarter Ended March 31, 2026Sai Parenterals Limited Reports Nil Utilization of IPO Proceeds for Quarter Ended March 31, 2026
Sai Parenterals Limited reported nil utilization of its IPO proceeds for the quarter ended March 31, 2026, with the entire fresh issue amount of INR 2,850 Million remaining in an Axis Bank escrow account. India Ratings & Research Private Limited, the appointed Monitoring Agency, confirmed no deviation from the objects stated in the Offer Document, based on management representation and a Statutory Auditor Certificate from R Kabra & Co. LLP. All planned expenditure objects, including capacity expansion, R&D centre establishment, debt repayment, and working capital requirements, remain ongoing with a Fiscal 2027 completion target. The report was filed with stock exchanges on May 12, 2026, in compliance with applicable SEBI regulations.
*this image is generated using AI for illustrative purposes only.
Sai Parenterals Limited, a pharmaceutical research and manufacturing company, has filed its Monitoring Agency Report for the quarter ended March 31, 2026, pursuant to Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report was prepared by India Ratings & Research Private Limited and submitted to the stock exchanges on May 12, 2026.
IPO Issue Overview
The company conducted its Initial Public Offer during March 2026, with the issue period running from March 24, 2026 to March 27, 2026, and an anchor issue date of March 23, 2026. The IPO comprised a fresh issue as well as an offer for sale component. The key issue details are summarised below:
| Parameter: | Details |
|---|---|
| Type of Issue: | Initial Public Offer (IPO) |
| Securities Offered: | 72,70,408 Equity Shares of FV ₹ 5 each @ ₹ 392 per Equity Share |
| Fresh Issue Size: | INR 2,850 Million |
| Offer for Sale Size: | INR 1,237.89 Mn |
| Total Issue Size: | INR 4,087.89 Mn |
| Issue Period: | March 24, 2026 to March 27, 2026 |
| Anchor Issue Date: | March 23, 2026 |
| Monitoring Agency: | India Ratings & Research Private Limited |
The promoters of the company are Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna.
Nil Utilization Reported for the Quarter
For the quarter ended March 31, 2026, the Monitoring Agency confirmed nil utilization of IPO proceeds across all stated objects. The entire fresh issue amount of INR 2,850.00 Million remains unutilized and is currently held in an Axis Bank escrow account (A/c: 926020003760575). No earnings, maturity date, or return on investment has been recorded for the funds during this period.
The utilization status against each object of the issue is presented below:
| Item Head: | Amount as per Offer Document (INR Million) | Amount Utilized (INR Million) | Total Unutilized (INR Million) |
|---|---|---|---|
| Capacity expansion and upgradation of manufacturing facilities: | 1,107.95 | - | 1,107.95 |
| Establishment of a new R&D Centre: | 180.23 | - | 180.23 |
| Repayment / prepayment of certain outstanding borrowings: | 143.02 | - | 143.02 |
| Working capital requirements: | 330.00 | - | 330.00 |
| Repayment of bridge loan and term loan (Sai Parenterals Pte Limited / Noumed Pharmaceuticals): | 356.41 | - | 356.41 |
| General Corporate Purposes: | 447.40 | - | 447.40 |
| Issue Related Expenses: | 284.99 | - | 284.99 |
| Total: | 2,850.00 | - | 2,850.00 |
No Deviation from Offer Document Objects
Based on the Management Representation and the Statutory Auditor Certificate dated May 8, 2026, issued by R Kabra & Co. LLP, Chartered Accountants (FRN – 104502W/W100721), the Monitoring Agency confirmed no deviation from the objects stated in the Offer Document. The means of finance for the disclosed objects have not changed, and no material deviations requiring shareholder approval were identified.
All six primary expenditure objects, along with issue-related expenses, are reported as ongoing with a target completion timeline of Fiscal 2027, consistent with the disclosures in the Offer Document. No delay in implementation has been recorded, and no unfavorable events affecting the viability of the objects were reported.
Deployment of Unutilized Proceeds
The full IPO proceeds of INR 2,850.00 Million continue to be held in the Escrow Axis Bank account pending deployment. There was nil utilization under the General Corporate Purposes head during the current quarter as well.
| Sr. No.: | Instrument / Entity: | Amount Invested (INR Million): |
|---|---|---|
| 1: | Lying in Escrow Axis Bank A/c: 926020003760575 | 2,850.00 |
| Total: | 2,850.00 |
The report was signed by Shrikant Dev, Company Secretary at India Ratings & Research Private Limited, on May 11, 2026, and submitted to the exchanges by Anil Kumar Karusala, Managing Director of Sai Parenterals Limited, on May 12, 2026.
How will Sai Parenterals prioritize the deployment of INR 2,850 million in IPO proceeds across its six stated objectives during Fiscal 2027, and which projects are likely to see funds deployed first?
What is the expected timeline and capacity increase for Sai Parenterals' manufacturing facility expansion, and how might this impact its competitive positioning in the parenteral pharmaceutical market?
How will the repayment of bridge and term loans for Sai Parenterals Pte Limited and Noumed Pharmaceuticals affect the company's consolidated balance sheet and interest cost savings going forward?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
